Collectively, this study provides the first evidence that osimertinib induces ER stress-related paraptosis in GBM cells, reveals a TRIP13-driven resistance mechanism against osimeritinib, suggesting that the AKT inhibitor MK-2206 might overcome this resistance. This evidence concerns the gene TRIP13 and glioblastoma.